Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab

Background  Chronic plaque psoriasis is associated with obesity, which is a metabolic and inflammatory disorder. Adipokines are involved in the pathogenesis of psoriasis and they are biomarkers of obesity‐related inflammation.

[1]  M. Okada,et al.  A novel adipocytokine, chemerin exerts anti-inflammatory roles in human vascular endothelial cells. , 2012, Biochemical and biophysical research communications.

[2]  K. Ahn,et al.  Chemerin and Adiponectin Contribute Reciprocally to Metabolic Syndrome , 2012, PloS one.

[3]  J. Olefsky,et al.  The cellular and signaling networks linking the immune system and metabolism in disease , 2012, Nature Medicine.

[4]  U. Müller-Ladner,et al.  Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis. , 2012, Experimental and molecular pathology.

[5]  U. Mrowietz,et al.  Adipokines and psoriasis , 2011, Experimental dermatology.

[6]  Jaewon Lee,et al.  Adipokine resistin is a key player to modulate monocytes, endothelial cells, and smooth muscle cells, leading to progression of atherosclerosis in rabbit carotid artery. , 2011, Journal of the American College of Cardiology.

[7]  P. Calzavara-Pinton,et al.  C-Reactive Protein and Markers for Thrombophilia in Patients with Chronic Plaque Psoriasis , 2010, International journal of immunopathology and pharmacology.

[8]  Yutaka Takahashi,et al.  Circulating level of chemerin is upregulated in psoriasis. , 2010, Journal of dermatological science.

[9]  Luis Puig,et al.  Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. , 2010, The Journal of investigative dermatology.

[10]  D. Goldgar,et al.  Obesity in early adulthood as a risk factor for psoriatic arthritis. , 2010, Archives of dermatology.

[11]  C. Albanesi,et al.  Immune functions and recruitment of plasmacytoid dendritic cells in psoriasis , 2010, Autoimmunity.

[12]  G. Rogler,et al.  Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease , 2010, Inflammatory bowel diseases.

[13]  Y. Moon,et al.  Resistin enhances the expansion of regulatory T cells through modulation of dendritic cells , 2010, BMC Immunology.

[14]  P. Gisondi,et al.  Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. , 2009, Journal of hepatology.

[15]  L. Naldi,et al.  European S3‐Guidelines on the systemic treatment of psoriasis vulgaris , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[16]  M. Parmentier,et al.  Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment , 2009, The Journal of experimental medicine.

[17]  B. Thiers.  Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis: Evidence from the Psocare Project , 2009 .

[18]  T. Yoshimura,et al.  Chemerin reveals its chimeric nature , 2008, The Journal of experimental medicine.

[19]  Carlo Tomino,et al.  Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis , 2008, Dermatology.

[20]  B. Strober,et al.  Effects of etanercept on C‐reactive protein levels in psoriasis and psoriatic arthritis , 2008, The British journal of dermatology.

[21]  James T. Elder,et al.  Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation , 2008, The British journal of dermatology.

[22]  T. Ohtsuka.  The relation between high‐sensitivity C‐reactive protein and maximum body mass index in patients with psoriasis , 2008, The British journal of dermatology.

[23]  S. Chimenti,et al.  Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. , 2008, Pharmacological research.

[24]  P. Gisondi,et al.  Anti–tumour necrosis factor‐α therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[25]  H. Tilg,et al.  Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. , 2008, Clinical science.

[26]  C. Day,et al.  Non-alcoholic fatty liver disease: the mist gradually clears. , 2008, Journal of hepatology.

[27]  F. Seibold,et al.  Resistin is an inflammatory marker of inflammatory bowel disease in humans , 2007, European journal of gastroenterology & hepatology.

[28]  O. Gualillo,et al.  The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. , 2007, Trends in cardiovascular medicine.

[29]  B. Strober,et al.  Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review , 2007, The British journal of dermatology.

[30]  S. Piaserico,et al.  Prevalence of metabolic syndrome in patients with psoriasis: a hospital‐based case–control study , 2007, The British journal of dermatology.

[31]  Manisha Talim,et al.  Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients , 2007, Diabetes Care.

[32]  H. Tilg,et al.  Visfatin , an Adipocytokine with Proinflammatory and Immunomodulating Properties 1 , 2007 .

[33]  U. Müller-Ladner,et al.  Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum , 2006, Annals of the rheumatic diseases.

[34]  Dafna Gladman,et al.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.

[35]  Bohan Wang,et al.  Acute and prolonged effects of TNF-α on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture , 2006, Pflügers Archiv.

[36]  Michael Hinckley,et al.  Impact of obesity and smoking on psoriasis presentation and management. , 2005, Archives of dermatology.

[37]  M. Matsuda,et al.  Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. , 2005, Science.

[38]  Reinhard Guthke,et al.  Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. , 2005, European journal of dermatology : EJD.

[39]  Anand Rohatgi,et al.  Resistin Is an Inflammatory Marker of Atherosclerosis in Humans , 2005, Circulation.

[40]  S. Feldman.  A quantitative definition of severe psoriasis for use in clinical trials , 2004, The Journal of dermatological treatment.

[41]  K. Wellen,et al.  Obesity-induced inflammatory changes in adipose tissue. , 2003, The Journal of clinical investigation.

[42]  Marc Parmentier,et al.  Specific Recruitment of Antigen-presenting Cells by Chemerin, a Novel Processed Ligand from Human Inflammatory Fluids , 2003, The Journal of experimental medicine.

[43]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.